← Back to headlines
Raymond James Adjusts Ratings for Korro Bio and Trade Desk Stocks
Raymond James has reiterated its rating for Korro Bio stock based on its hyperammonemia outlook, while simultaneously downgrading Trade Desk stock due to a weak outlook. These adjustments reflect changing market perspectives on both companies.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
